Gasterointestinal enteritis necroticans is caused by –
**Question:** Gasterointestinal enteritis necroticans is caused by -
**Core Concept:** Gasterointestinal enteritis necroticans (GIN) is a clinical condition characterized by necrotic enteritis in humans, primarily affecting immunocompromised individuals. The condition is caused by a particular bacterium, typically Clostridium perfringens, which releases toxins leading to tissue damage and necrosis in the gastrointestinal tract.
**Why the Correct Answer is Right:** Clostridium perfringens is a Gram-positive, anaerobic bacterium that belongs to the family Clostridiaceae and produces numerous toxins, including alpha, beta, epsilon, and iota toxins. These toxins are responsible for the necrotic enteritis observed in GIN.
**Why Each Wrong Option is Incorrect:**
A. **Gastroenteritis necroticans (GNE)** is a similar condition caused by Clostridium septicum, a different bacterium that also produces toxins, but it is not the correct answer for GIN.
B. **Gastritis necroticans (GN)** is a different condition characterized by necrotic gastritis, caused by various pathogens like Helicobacter pylori, but it is not the correct answer for GIN.
C. **Enteritis necrotica** is a condition characterized by necrotic enteritis, caused by various pathogens like Campylobacter jejuni or Escherichia coli, but it is not the correct answer for GIN.
D. **Clostridium perfringens type C** is a specific strain of C. perfringens, known to cause necrotic enteritis, but the correct answer is C. perfringens itself, not a specific type.
**Clostridium perfringens is the correct answer because:**
- It is the causative agent of GIN, producing various toxins responsible for necrotic enteritis.
- C. perfringens is the broader term for the correct answer, while type C is a specific strain that can cause the condition.
**Clinical Pearl:** Gastric emptying studies may be performed to assess the severity of GIN and guide treatment decisions, as the condition is often associated with impaired gastric emptying in immunocompromised patients.